Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Switzerland - Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced that the European Commission granted conditional marketing authorization for KRAZATI as a...

Related Keywords

Switzerland ,Liechtenstein ,Norway ,Germany ,Grosshansdorf ,Schleswig Holstein ,Iceland ,Martin Reck ,Charles Baum ,European Commission ,Exchange Commission ,European Union ,Union Register ,Committee For Medicinal Products Human Use ,European Medicines Agency ,Nasdaq ,Mirati Therapeutics Inc ,Lung Clinic ,Medicinal Products ,Human Use ,Product Characteristics ,Medicines Agency ,News Publishing ,Markets ,